Every 8-K that OmniAb, Inc. Warrant (OABIW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OABIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OABIW filings page.
OmniAb, Inc. reported Q2 2026 revenue of $13.4 million, up from $3.9 million a year earlier, driven mainly by milestone revenue along with higher service and xPloration sales. Net loss narrowed to $5.9 million, or $0.05 per share, while total costs and operating expenses were flat at $20.1 million and cash costs were $13.3 million.
For the first half of 2026, revenue was $27.8 million compared with $8.1 million in 2025, and net loss improved to $13.6 million, or $0.11 per share. Total costs and operating expenses were $42.3 million, including higher non-cash amortization tied to a prior impairment. Cash, cash equivalents and short-term investments totaled $52.0 million as of June 30, 2026.
OmniAb raised 2026 guidance, now expecting revenue of $32–$36 million, GAAP costs and operating expenses of $84–$88 million, non-GAAP cash costs of $51–$55 million, and year-end cash of $37–$41 million with an effective tax rate of approximately 0%. The company highlighted 110 active partners, 425 active programs, and multiple partner-led assets advancing into or toward Phase 3 studies.
OmniAb, Inc. appointed Amechi Nwachuku as Chief Operating Officer effective July 13, 2026. He is a life sciences executive with over two decades of commercial and leadership experience at Thermo Fisher Scientific, Danaher operating companies SCIEX and Beckman Coulter Diagnostics, Johnson & Johnson, and Bayer, and holds both an M.B.A. and B.S. from MIT.
His compensation includes an initial annual base salary of $445,000, eligibility for an annual target bonus equal to 45% of base salary (prorated for 2026), and a $20,000 signing bonus. Effective August 1, 2026, he received stock options to purchase 800,000 shares of OmniAb common stock under the 2022 Incentive Award Plan, with 12.5% vesting six months after grant and the balance vesting in equal monthly installments thereafter, subject to continued service, at an exercise price equal to the Nasdaq closing price on the grant date.
He participates in the OmniAb Severance Plan, which provides cash severance equal to base salary for a period of two months plus one week per year of service and continued health coverage at existing cost levels during that period upon an involuntary termination without cause, subject to a release. He has a separate change in control severance agreement that, if he is terminated without cause or resigns for good reason within 24 months after a change in control, provides a lump-sum benefit equal to one times annual base salary, plus one times the greater of the maximum target bonus for the year of termination or change in control, plus 12 times his monthly health coverage premium. In that case, all time-based equity awards fully vest and the post-termination stock option exercise period extends to nine months, not beyond the original expiration date, conditioned on a general release of claims.
OmniAb, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026. Shareholders elected two Class I directors to three-year terms ending at the 2029 Annual Meeting. Jennifer Cochran, Ph.D. received 57,948,696 votes for and 25,997,984 withheld, with 18,464,904 broker non-votes. Matthew W. Foehr received 82,231,849 votes for and 1,714,831 withheld, with 18,464,904 broker non-votes.
Shareholders also ratified the appointment of Ernst & Young LLP as OmniAb’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,163,551 votes for, 112,653 against, and 135,380 abstentions.
OmniAb reported a much stronger first quarter of 2026, with revenue rising to $14.4 million from $4.2 million a year earlier, mainly on higher milestone revenue. Total GAAP costs and operating expenses were $22.3 million, roughly flat year over year, while non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
Net loss narrowed to $7.7 million, or $0.06 per share, compared with $18.2 million, or $0.17 per share, in the prior‑year quarter. OmniAb raised 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million, reflecting confidence in partner progress and its technology platform.
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.